Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366171 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension Study of Bifeprunox
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00366171 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 120 participants.
The verdict
NCT00366171, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.
Interventions
- DRUG Bifeprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366171
The ClinicalTrials.gov registry entry for NCT00366171 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bifeprunox is the first listed.
NCT00366171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366171 about?
NCT00366171 is a clinical study titled "Open Label Extension Study of Bifeprunox". A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.
What is the current status of trial NCT00366171?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2006-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00366171?
The interventions under investigation include: Bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00366171?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.